Why Pharma Companies Need VAPT Against Cyberattacks

Pharmaceutical companies in India operate across research, drug discovery, clinical trials, manufacturing, healthcare partnerships, cloud platforms, laboratories, supply chains, and digital applications. These environments contain valuable intellectual property, sensitive clinical information, research data, employee credentials, commercial records, and systems that increasingly connect with external partners. As pharmaceutical operations become more digital, the number of systems that can potentially be exposed to cyber threats also increases.

For pharmaceutical organizations, cybersecurity is not limited to protecting corporate networks. Security teams also need to consider web applications, APIs, mobile applications, cloud environments, research platforms, clinical trial portals, databases, laboratory systems, and connections with Contract Research Organizations (CROs) and other third parties.

Vulnerability Assessment and Penetration Testing (VAPT) provides a practical way to identify security weaknesses and determine whether vulnerabilities can be exploited under controlled testing conditions. For pharmaceutical companies, VAPT can form an important first line of technical defense by exposing weaknesses before attackers can use them against critical applications, data, and infrastructure.

Identify Vulnerabilities Before Attackers Exploit Them. Evaluate applications, networks, APIs, and infrastructure for security weaknesses through VAPT. Explore VAPT Services With INTERCERT.

Why Pharmaceutical Companies Are Prime Targets for Cyberattacks

The pharmaceutical industry combines high-value information with complex digital environments. Drug discovery can involve years of research and substantial investment, while clinical programs generate sensitive information associated with participants, investigators, sponsors, and research outcomes. Pharmaceutical companies also exchange information with CROs, research institutions, healthcare organizations, suppliers, technology providers, and regulators.

This combination creates several attractive attack surfaces. An attacker may target an internet-facing application, compromise an employee account, exploit an API, gain access through a third-party connection, or target a vulnerable cloud environment.

The pharmaceutical sector has also appeared in analyses of cyber incidents affecting the health sector. ENISA's health threat landscape covering incidents from January 2021 through March 2023 identified attacks against the pharmaceutical industry among the incidents analyzed, while ransomware was identified as a major threat across the health sector.

Pharmaceutical Intellectual Property as a High-Value Target

Pharmaceutical intellectual property can include drug discovery research, molecular information, formulation data, laboratory results, clinical research information, manufacturing processes, patents, proprietary algorithms, and other commercially sensitive information. Unauthorized access to this information can create commercial, legal, and competitive consequences.

A successful attack does not necessarily need to disrupt production to cause significant damage. Theft of research information or unauthorized access to a development environment can expose commercially sensitive information before a product reaches the market.

Pharmaceutical intellectual property cybersecurity therefore needs to consider not only where information is stored, but also how users, applications, APIs, cloud services, researchers, CROs, and other partners access that information.

Sensitive Clinical Trial and Patient Data

Clinical trials generate multiple categories of sensitive information. Depending on the trial and system involved, environments may contain participant information, clinical observations, laboratory results, investigator records, consent-related information, study documentation, and other research data.

The Central Drugs Standard Control Organization's Indian Good Clinical Practice material recognizes electronic case report forms and electronic clinical study records as part of clinical research data management.

Clinical trial cybersecurity testing should therefore examine the security of applications and systems that store, transmit, process, or provide access to trial-related information. Weak authentication, excessive privileges, insecure APIs, exposed databases, and application vulnerabilities can create opportunities for unauthorized access.

Increasing Digitalization Across Pharma Operations

Pharmaceutical organizations increasingly depend on interconnected technologies for research, laboratory operations, manufacturing, supply chain management, employee collaboration, data analysis, cloud services, and external communication.

Digital transformation can increase efficiency, but it can also increase the number of connected systems and interfaces that security teams need to monitor. A web portal may communicate with multiple APIs. A clinical platform may exchange information with a CRO. A research application may use cloud storage and third-party services.

Each connection introduces another component that should be evaluated from a security perspective.

Third-Party and Supply Chain Cybersecurity Risks

Pharmaceutical companies rarely operate in isolation. CROs, laboratories, technology vendors, cloud providers, logistics providers, research partners, consultants, and other suppliers can have legitimate access to systems or information.

A third-party connection can create an indirect route into a pharmaceutical environment if access controls, APIs, authentication mechanisms, or externally exposed systems contain weaknesses.

VAPT can include testing of authorized third-party-facing applications, APIs, portals, and network interfaces to determine whether security weaknesses could expose the organization's systems or information.

Common Cybersecurity Threats Facing Pharmaceutical Companies

Pharmaceutical organizations face a combination of conventional cyber threats and risks specific to research-intensive, data-rich environments. Security priorities vary according to the organization's technology stack, business model, data types, external exposure, and third-party relationships.

Ransomware and Data Extortion

Ransomware can affect availability by preventing organizations from accessing systems and data. Modern attacks can also involve data theft and subsequent extortion.

Healthcare remains an attractive target for ransomware and system intrusion. Verizon's 2025 DBIR reported 1,710 incidents in the healthcare sector, including 1,542 incidents involving confirmed data disclosure, with system intrusion identified among the leading patterns.

For pharmaceutical companies, ransomware exposure may extend beyond office systems to research platforms, manufacturing-related environments, laboratory applications, file repositories, and other critical technology assets.

Intellectual Property Theft

Attackers may target proprietary research because pharmaceutical intellectual property can have substantial commercial value. Credentials, exposed applications, vulnerable APIs, compromised cloud environments, and poorly protected databases can become routes to sensitive research information.

VAPT can identify technical weaknesses that could expose applications or systems containing proprietary information. The objective is to determine whether an identified weakness can provide unauthorized access or other meaningful security impact.

Credential Theft and Unauthorized Access

Compromised credentials can give attackers legitimate-looking access to applications and services. Weak authentication controls, insecure session handling, excessive privileges, and authorization flaws can increase the consequences of credential compromise.

Testing should examine whether users can access information or functions beyond their intended permissions and whether authentication mechanisms can withstand common attack techniques.

Web Application and API Attacks

Pharmaceutical portals, research applications, supplier platforms, clinical trial systems, patient-facing applications, and internal tools may expose web interfaces or APIs.

OWASP's current Top 10:2025 identifies broken access control, security misconfiguration, software supply chain failures, cryptographic failures, injection, insecure design, and authentication failures among the major web application security risks.

APIs can present additional risks because they frequently expose application functionality and data. OWASP's API Security Top 10 includes broken object-level authorization, broken authentication, broken function-level authorization, security misconfiguration, improper inventory management, and unsafe API consumption among its identified risks.

Insider and Third-Party Security Risks

Not every security incident originates from an unknown external attacker. Authorized users, compromised accounts, suppliers, contractors, and third-party systems can create security exposure.

VAPT can examine whether authorized access can be misused to reach restricted functions or information. This is particularly relevant where pharmaceutical systems have multiple user roles, external collaborators, and integrations.

Why Pharmaceutical R&D Systems Require Stronger Cybersecurity

Research environments can contain information that is commercially valuable long before a pharmaceutical product reaches the market. R&D environments may also involve specialized applications, laboratory systems, cloud services, databases, analytical tools, and external research relationships.

Security testing should account for the specific technologies and access patterns used by pharmaceutical research teams rather than treating R&D systems like ordinary corporate applications.

Protecting Drug Discovery and Research Data

Drug discovery platforms can contain research results, compound information, experimental data, analytical findings, and other proprietary information. Unauthorized access could expose research programs or provide attackers with commercially valuable information.

VAPT can examine the applications, APIs, authentication mechanisms, and externally accessible interfaces associated with these environments.

Securing Pharmaceutical Intellectual Property

Pharmaceutical IP protection cybersecurity requires attention to both infrastructure and application-level security. A secure perimeter does not eliminate the risk of an application vulnerability or authorization flaw.

Penetration testing for pharma data security can determine whether an attacker could move from an exposed application into sensitive resources or access information beyond the permissions assigned to a legitimate user.

Protecting Cloud-Based R&D Environments

Cloud services are increasingly used for data storage, research collaboration, application hosting, analytics, and other activities. Misconfigured access controls, exposed storage, weak identity controls, vulnerable applications, and insecure APIs can create cloud security risks.

ISO/IEC 27017:2026 addresses information security controls relevant to cloud services and applies across public, private, and hybrid cloud environments.

VAPT can complement broader cloud security controls by testing the externally reachable applications, APIs, and authorized attack surfaces associated with cloud-hosted R&D environments.

Securing Collaboration Between Pharma Companies, CROs, and Partners

CROs and research partners may exchange sensitive information through portals, APIs, file-sharing platforms, and other digital channels. The security of these connections matters because an exposed interface can become an entry point into sensitive information.

Testing should consider user roles, authentication, authorization, API security, exposed endpoints, data transmission, and access boundaries between participating organizations.

What Is VAPT and How Does It Work?

Vulnerability Assessment and Penetration Testing combines vulnerability identification with controlled security testing. Vulnerability assessment focuses on identifying known or suspected weaknesses, while penetration testing goes further by testing whether selected weaknesses can actually be exploited within an agreed scope.

For pharmaceutical organizations, VAPT can cover applications, APIs, mobile applications, networks, cloud environments, servers, databases, and other authorized assets.

The value of VAPT comes from connecting technical weaknesses to actual security impact. A vulnerability that appears significant in an automated scan may have limited practical impact, while a less obvious application or authorization weakness may provide a route to sensitive data.

Vulnerability Assessment vs Penetration Testing

Vulnerability assessment generally focuses on identifying and classifying security weaknesses across defined assets. It may use automated scanners, configuration checks, vulnerability databases, and other technical techniques.

Penetration testing involves controlled attempts to exploit identified or suspected weaknesses. Testers may examine whether an attacker can bypass authentication, access another user's information, escalate privileges, execute unauthorized functions, or reach protected resources.

Using both approaches gives pharmaceutical security teams a broader view of weaknesses and their practical security impact.

Identifying Vulnerabilities in Pharma IT Environments

A pharmaceutical VAPT scope can include internet-facing applications, internal applications, APIs, mobile applications, cloud services, network infrastructure, databases, portals, and selected research systems.

The scope should reflect the actual technology environment and the risks associated with the systems being tested.

Validating Exploitable Security Weaknesses

A vulnerability becomes more meaningful when testing demonstrates what an attacker could actually achieve through it. Controlled exploitation can establish whether a weakness results in unauthorized data access, privilege escalation, account compromise, application manipulation, or another security impact.

Testing should be carefully scoped for sensitive pharmaceutical and clinical environments so that security validation does not unnecessarily disrupt critical operations or alter protected research records.

Prioritizing Critical Security Findings

VAPT findings should be considered according to factors such as exploitability, affected assets, data sensitivity, user privileges, exposure, business impact, and attack paths.

A critical vulnerability in an internet-facing clinical application may require a different response priority from a low-impact issue in an isolated development environment.

VAPT for Pharmaceutical Data Security

Pharmaceutical data security extends across research information, clinical data, intellectual property, employee information, commercial records, supplier information, and other sensitive datasets.

VAPT for pharmaceutical data security focuses on the technical weaknesses that could expose these information assets through applications, APIs, authentication systems, cloud environments, or network interfaces.

Identifying Unauthorized Data Exposure

Testing can examine whether applications disclose information to unauthorized users through URLs, API parameters, responses, error messages, files, database queries, or other application functions.

Broken access control is particularly important because authorization failures can allow users to view, modify, or delete information outside their intended permissions. OWASP's 2025 Top 10 continues to place broken access control at number one.

Testing Authentication and Access Controls

Authentication confirms who a user is, while authorization determines what that user can access or do.

VAPT can examine login mechanisms, session management, password policies, multi-factor authentication flows where applicable, role-based access controls, privilege boundaries, account recovery processes, and authorization checks.

Protecting Sensitive Pharmaceutical Information

Sensitive information should not become accessible simply because a user knows a URL, changes an identifier, manipulates an API request, or accesses a hidden application function.

Testing can identify these weaknesses and demonstrate whether access controls work consistently across the application's different functions.

Reducing Risks to Pharmaceutical Intellectual Property

VAPT cannot eliminate all threats to pharmaceutical intellectual property, but it can identify exploitable technical weaknesses that may create unauthorized access to research applications and data.

This makes penetration testing for pharma data security a useful component of a broader information security program.

VAPT for Clinical Trial Systems

Clinical trial systems can process sensitive information and may connect sponsors, investigators, CROs, research sites, laboratories, and other parties.

India's clinical research framework includes requirements around maintaining trial-related records and protecting the rights, safety, and well-being of trial participants. CDSCO materials also describe electronic clinical study records and related data management processes.

Security testing for clinical trial systems should therefore consider the applications and interfaces used to capture, process, transmit, and access trial information.

Security Testing for Clinical Trial Applications

Clinical trial applications can include investigator portals, electronic data capture systems, sponsor portals, trial management platforms, participant-facing applications, and other research technologies.

Testing can examine application functionality, authentication, authorization, session management, input validation, data exposure, API security, and business logic.

Testing Patient and Research Data Protection

Where clinical systems contain personal or sensitive information, security testing should determine whether unauthorized users can access records, modify information, enumerate users, or retrieve information through application weaknesses.

India's Digital Personal Data Protection Act, 2023 establishes a legal framework concerning the processing of digital personal data. Its application to a particular pharmaceutical environment depends on the relevant processing activities and provisions in force.

Identifying Authentication and Authorization Weaknesses

Clinical systems may contain multiple roles, including investigators, sponsors, administrators, data managers, and other users. Incorrectly configured privileges can result in users accessing functions or records beyond their intended role.

VAPT can test role boundaries and determine whether authorization controls are consistently enforced.

Penetration Testing for Clinical Trial APIs and Portals

Clinical trial APIs may transfer information between applications, research sites, sponsors, CROs, and other systems. OWASP identifies broken object-level authorization and broken authentication as significant API security risks.

Penetration testing for clinical trial systems can therefore include API endpoint discovery, authentication testing, authorization testing, parameter manipulation, data exposure testing, rate-limit testing, and business logic validation where appropriate.

VAPT for Pharmaceutical Applications

Pharmaceutical applications can range from public websites to complex research platforms and internal enterprise systems. The security testing approach should reflect the application's function, exposure, data sensitivity, user population, and technical architecture.

Web Application Penetration Testing

Web application penetration testing examines security weaknesses in browser-based applications and their server-side components.

For pharmaceutical applications, testing may cover authentication, authorization, session management, input validation, file handling, business logic, data exposure, security headers, configuration, and application workflows.

API Security Testing

APIs can expose sensitive information and business functions to internal or external consumers. Testing should verify whether API endpoints properly authenticate users and enforce authorization at the object and function levels.

OWASP's API Security Top 10 specifically identifies broken object-level authorization and broken function-level authorization as API risks that can expose data or unauthorized functionality.

Mobile Application Penetration Testing

Mobile applications used by pharmaceutical employees, investigators, patients, field teams, or other authorized users can contain sensitive information and connect to backend APIs.

Testing can examine local data storage, authentication, session handling, API communication, certificate validation, application permissions, insecure data exposure, and backend authorization.

Authentication and Authorization Testing

Authentication and authorization should be tested separately because proving a user's identity does not automatically prove that the user is permitted to access every application function.

Testing can determine whether standard users can access administrative functions, whether users can access other users' records, and whether privileged functions are adequately protected.

Business Logic and Data Exposure Testing

Some vulnerabilities cannot be identified through conventional automated scanning because they involve how an application is designed to perform business operations.

For example, a system may technically authenticate users correctly but fail to enforce a business rule that prevents one investigator from accessing another investigator's records.

Business logic testing examines these application-specific workflows and authorization boundaries.

VAPT for Pharmaceutical R&D Systems

Pharmaceutical R&D systems can include laboratory applications, electronic laboratory notebooks, research databases, analytical platforms, file repositories, cloud environments, and specialized software.

The exact technologies differ between organizations, so VAPT scope should be based on the systems actually used by the research environment.

Testing Research and Laboratory Applications

Laboratory applications may process experimental information, test results, sample information, research records, or other sensitive data.

Testing can focus on authentication, authorization, input validation, exposed services, application configurations, APIs, and data access paths.

Protecting Drug Discovery Platforms

Drug discovery platforms may contain information associated with compounds, research results, experiments, models, and development activities.

Security testing can identify technical weaknesses that could allow unauthorized users to reach these systems or retrieve information from protected resources.

Securing R&D Databases and Data Repositories

Databases and repositories can become high-value targets when they contain large volumes of research information. VAPT can examine externally exposed interfaces, application access controls, database-connected applications, authentication mechanisms, and data retrieval functions.

Direct testing of production databases should be carefully scoped to prevent unnecessary changes to research information.

Testing External and Internal Attack Surfaces

External attack surfaces include internet-facing applications, portals, APIs, remote access services, and public infrastructure.

Internal attack surfaces can include applications and services accessible after an attacker compromises an employee account or gains access to an internal network.

Considering both perspectives can provide a more realistic picture of how an attacker might progress through a pharmaceutical environment.

Key Vulnerabilities VAPT Can Identify in Pharma Environments

VAPT can identify many categories of vulnerabilities, but findings depend on the technology, configuration, scope, and testing methodology used.

Broken Access Control

Broken access control occurs when an application does not properly restrict what authenticated or unauthenticated users can access or perform.

For pharmaceutical applications, this could expose research records, clinical information, administrative functions, or proprietary data.

Authentication Vulnerabilities

Authentication weaknesses can involve insecure login mechanisms, weak session handling, credential exposure, account recovery flaws, or other weaknesses that allow unauthorized users to gain access.

OWASP's 2025 Top 10 includes authentication failures as a major web application security category.

Injection Vulnerabilities

Injection vulnerabilities occur when untrusted input is processed by an interpreter or backend component in an unsafe manner. Depending on the technology, this can affect databases, operating systems, applications, or other processing components.

Sensitive Data Exposure

Applications may expose sensitive information through API responses, error messages, files, logs, browser storage, URLs, or incorrectly configured access controls.

Testing can determine whether sensitive information is available to users or systems that should not have access to it.

Security Misconfiguration

Security misconfiguration can occur when unnecessary services are exposed, security settings are weak, default configurations remain active, access controls are overly permissive, or systems disclose excessive technical information.

API Security Vulnerabilities

API vulnerabilities can involve broken authorization, authentication weaknesses, excessive data exposure, unrestricted resource consumption, security misconfiguration, and other API-specific issues.

Business Logic Vulnerabilities

Business logic vulnerabilities arise when an application allows actions that violate intended business rules. These weaknesses often require manual testing because the expected behavior depends on the specific pharmaceutical application and its workflows.

When Should Pharmaceutical Companies Conduct VAPT?

There is no single testing frequency that applies to every pharmaceutical organization. Testing intervals should consider application exposure, change frequency, risk, regulatory or contractual requirements, previous findings, and the sensitivity of the systems involved.

Before Launching New Applications

Security testing before production release can identify vulnerabilities while applications are still being prepared for users. This can be particularly relevant for new clinical portals, research platforms, APIs, mobile applications, and external partner portals.

After Major Application or Infrastructure Changes

Significant changes to application architecture, authentication, APIs, cloud infrastructure, network exposure, or third-party integrations can introduce new security risks.

Testing after material changes can determine whether the modified environment contains exploitable weaknesses.

During Clinical Trial Technology Deployments

Clinical trial applications should be considered within the security planning for new or significantly modified trial technology. Testing can focus on participant-facing interfaces, investigator portals, APIs, authentication, authorization, and data handling.

Periodically for Internet-Facing Systems

Internet-facing applications are continuously exposed to potential attackers. Periodic penetration testing can identify weaknesses introduced through application updates, infrastructure changes, new dependencies, or configuration changes.

After Significant Security Changes

Changes to identity systems, access controls, network architecture, cloud environments, security controls, or application components can alter the attack surface.

Testing after significant changes can provide additional assurance that critical security boundaries remain effective.

Building VAPT Into a Pharmaceutical Cybersecurity Strategy

VAPT works most effectively when testing is connected to the organization's broader cybersecurity risk management activities. A pharmaceutical company should consider which systems contain the most sensitive information and which applications have the greatest external exposure.

Prioritizing Critical Pharma Applications

Not every application carries the same level of risk. Systems containing pharmaceutical IP, clinical information, research data, administrative privileges, or sensitive business information may warrant greater testing attention.

Testing Internet-Facing Assets

Public-facing websites, portals, APIs, remote access systems, and cloud-hosted applications can be accessible to attackers from outside the organization.

These assets should be included in the organization's security testing scope according to their risk and business importance.

Including Third-Party and API Connections

Third-party integrations should not be overlooked. APIs, partner portals, cloud services, data exchanges, and remote connections can create additional attack paths.

Testing should establish clear authorization boundaries and determine whether externally accessible interfaces expose sensitive functions or information.

Retesting Identified Vulnerabilities

Retesting verifies whether previously identified vulnerabilities remain exploitable after corrective changes have been made.

This is particularly important for high-risk findings affecting internet-facing applications, clinical systems, APIs, and R&D platforms.

VAPT and Pharmaceutical Cybersecurity Standards

VAPT should be considered alongside broader information security standards and organizational security controls rather than treated as a substitute for an information security management system.

VAPT and ISO/IEC 27001

ISO/IEC 27001:2022 specifies requirements for an information security management system and provides a framework for managing information security risks.

Security testing can form part of a broader information security program by providing technical evidence about vulnerabilities and the effectiveness of selected security controls.

For pharmaceutical companies, VAPT can be particularly relevant to applications and systems within the defined information security scope.

VAPT and ISO/IEC 27017

ISO/IEC 27017 addresses information security controls relevant to cloud services. The current 2026 edition provides cloud-specific controls and clarifies security responsibilities between cloud service customers and providers.

For pharmaceutical organizations using cloud platforms for research, applications, data storage, or collaboration, VAPT can examine the security of authorized cloud-hosted applications and interfaces.

VAPT and ISO/IEC 27018

ISO/IEC 27018:2025 focuses on protecting personally identifiable information in public cloud environments where the cloud service provider acts as a PII processor.

For pharmaceutical organizations using public cloud services to process personal information, the standard can be considered alongside privacy and information security requirements. VAPT can provide technical testing of relevant applications and interfaces within scope.

VAPT Within a Broader Information Security Program

VAPT is one technical security activity within a broader cybersecurity program. It does not replace secure software development, identity and access management, vulnerability management, network security, logging, monitoring, incident response, employee security controls, or third-party risk management.

For pharmaceutical companies, combining these activities creates a more complete view of cybersecurity risk across applications, infrastructure, people, data, and external relationships.

Test Your Security Against Real-World Attack Scenarios. VAPT combines Vulnerability Assessment and Penetration Testing to evaluate potential security weaknesses. Explore VAPT With INTERCERT.

VAPT Checklist for Pharmaceutical Companies

A pharmaceutical VAPT program should be based on the organization's technology environment and risk profile. The following areas can form a practical starting point for defining testing scope.

Applications and APIs

Identify internet-facing and internally accessible applications, APIs, authentication endpoints, administrative functions, third-party integrations, and sensitive data flows. Verify that authorization controls operate correctly across user roles and API endpoints.

Clinical Trial Systems

Include relevant clinical trial portals, electronic data capture applications, investigator interfaces, APIs, authentication mechanisms, and data access functions within the authorized testing scope.

R&D Systems

Consider research applications, laboratory platforms, cloud-hosted R&D environments, databases, file repositories, APIs, and other systems that contain pharmaceutical research information.

Authentication and Access Controls

Review authentication mechanisms, session handling, role-based permissions, privilege boundaries, account recovery, administrative access, and authorization checks.

Sensitive Data Protection

Determine whether personal information, clinical data, research information, intellectual property, credentials, or other sensitive data can be accessed through unauthorized application functions or exposed interfaces.

Vulnerability Retesting

After vulnerabilities have been addressed, retesting can determine whether the identified weaknesses have been effectively resolved within the tested scope.


Read More:
Why VAPT Services Are Essential for Modern Cybersecurity?
Why Are VAPT Services Critical for Strengthening Business Security?